Top 10 Companies in the Samarium‑153 EDTMP Bone Pain Palliation Radiopharmaceutical Market (2026): Market Leaders Powering Global Oncology Care

MARKET INSIGHTS

The global Samarium‑153 EDTMP Bone Pain Palliation Radiopharmaceutical Market size was valued at USD 0.18 billion in 2025. The market is projected to grow from USD 0.19 billion in 2026 to USD 0.32 billion by 2034, exhibiting a CAGR of 6.7% during the forecast period.

Samarium‑153 EDTMP, also known as samarium‑153 lexidronam or Quadramet, is a radiopharmaceutical agent designed specifically for the palliation of bone pain associated with osteoblastic metastatic bone lesions. This beta‑emitting radioisotope complex targets areas of high bone turnover, delivering localized radiation to relieve severe pain in patients with cancers such as prostate, breast, and lung cancer that have spread to the bones. It provides targeted relief by accumulating preferentially in metastatic sites while minimizing damage to surrounding healthy tissue.

The market is experiencing steady growth driven by the rising global incidence of cancers that frequently metastasize to bone, an aging population, and increasing awareness of radiopharmaceutical therapies for palliative care. While systemic analgesics and other treatments remain common, Samarium‑153 EDTMP offers an effective alternative or adjunct for patients who do not respond adequately to conventional pain management, often providing relief within one week that can last several months. Furthermore, advancements in nuclear medicine infrastructure and improved access to radiopharmaceutical production facilities are supporting broader adoption. Key players continue to invest in supply chain enhancements and next‑generation formulations to address limitations such as short half‑life and myelosuppression risks, ensuring reliable availability for clinical use. Ongoing research also explores its potential beyond palliation toward combined therapeutic applications.

Samarium‑153 EDTMP Bone Pain Palliation Radiopharmaceutical Market – View in Detailed Research Report

🔟 1. Lantheus Medical Imaging

Headquarters: United States
Key Offering: Quadramet® (Samarium‑153 EDTMP) for bone pain palliation

Lantheus remains the dominant manufacturer of Samarium‑153 EDTMP, leveraging its FDA‑approved product and an integrated supply chain that includes cyclotron‑based isotope production and proprietary chelation technology. The company controls a substantial share of the commercial market and supplies the majority of hospitals in North America and Europe, creating high entry barriers for new entrants.

Sustainability & Growth Initiatives:

• Investing in supply‑chain resilience and next‑generation formulations to reduce myelosuppression risks
• Expanding production capacity to meet growing global demand
• Enhancing regulatory compliance and quality assurance across all manufacturing sites
• Collaborating with academic and clinical partners to explore theranostic applications

🔟 2. Curium

Headquarters: France
Key Offering: Samarium‑153 production and distribution for oncology centers in the EU

Curium supplies Samarium‑153 through a partnership with healthcare distributors, focusing on personalized dosing for oncology centers. The company emphasizes local production and cost‑effective solutions tailored to regional needs.

Sustainability & Growth Initiatives:

• Strengthening local production capabilities to reduce transport logistics
• Providing personalized dosing solutions to improve patient outcomes
• Expanding distribution networks across the EU
• Investing in research collaborations to enhance formulation quality

🔟 3. IBA

Headquarters: Belgium
Key Offering: Cyclotron‑produced Samarium‑153 as part of a broader radionuclide portfolio for research hospitals

IBA offers on‑site isotope generation, supporting research hospitals that require immediate access to high‑purity Samarium‑153. Their technology reduces reliance on external suppliers and enhances clinical flexibility.

Sustainability & Growth Initiatives:

• Expanding on‑site production facilities to support growing demand
• Providing advanced training for nuclear medicine personnel
• Collaborating with research institutions to develop novel radiopharmaceuticals
• Ensuring rigorous quality control and regulatory compliance

🔟 4. ANSTO

Headquarters: Australia
Key Offering: Samarium‑153 for regional clinics in Oceania, focusing on cost‑effective production for public health systems

ANSTO supplies Samarium‑153 to regional clinics, emphasizing affordable production and broad accessibility for public health services.

Sustainability & Growth Initiatives:

• Optimizing production processes to reduce costs and waste
• Expanding distribution to underserved regions
• Partnering with government health agencies to improve access
• Investing in workforce development for nuclear medicine specialists

🔟 5. Institute of Isotopes – JSC

Headquarters: Russia
Key Offering: Samarium‑153 distribution in Eastern Europe through government‑backed channels

Institute of Isotopes – JSC serves Eastern European markets with reliable distribution, leveraging government support to ensure consistent supply.

Sustainability & Growth Initiatives:

• Strengthening government partnerships to secure supply chains
• Expanding regional coverage across Eastern Europe
• Investing in quality assurance and regulatory alignment
• Supporting local production facilities to reduce transport times

🔟 6. Radiopharma Solutions

Headquarters: Canada
Key Offering: Radiopharmacy compounding and patient‑specific treatment planning

Radiopharma Solutions offers value‑added services such as radiopharmacy compounding and individualized therapy planning, enhancing the precision and safety of Samarium‑153 administration.

Sustainability & Growth Initiatives:

• Implementing advanced compounding protocols to ensure high purity
• Providing personalized treatment plans based on patient biomarkers
• Expanding service offerings to include quality‑assurance audits
• Collaborating with oncology centers to streamline workflow

🔟 7. NuTech Radiopharma

Headquarters: Japan
Key Offering: Radiopharmacy compounding and patient‑specific therapy solutions

NuTech Radiopharma is emerging as a provider of advanced compounding services, focusing on patient‑specific treatment planning and high‑quality radiopharmaceuticals.

Sustainability & Growth Initiatives:

• Investing in cutting‑edge compounding technology
• Developing personalized dosing protocols
• Partnering with academic centers for clinical research
• Ensuring strict adherence to regulatory standards

🔟 8. Jubilant Life Sciences

Headquarters: India
Key Offering: Production and distribution of Samarium‑153 EDTMP for the Indian market

Jubilant Life Sciences has expanded its manufacturing capacity to meet the growing demand for Samarium‑153 in India, providing cost‑effective access to patients across the country.

Sustainability & Growth Initiatives:

• Scaling up production facilities to increase output
• Implementing quality‑control measures to meet international standards
• Expanding distribution networks across India and neighboring regions
• Collaborating with healthcare providers to improve patient access

🔟 9. Cardinal Health

Headquarters: United States
Key Offering: Distribution of radiopharmaceuticals, including Samarium‑153 EDTMP, to hospitals and oncology clinics

Cardinal Health offers a broad distribution network, ensuring timely delivery of Samarium‑153 to healthcare facilities worldwide, thereby supporting patient access and treatment continuity.

Sustainability & Growth Initiatives:

• Expanding logistics and cold‑chain capabilities for radiopharmaceuticals
• Providing educational resources for clinicians and pharmacists
• Enhancing supply‑chain resilience through diversified sourcing
• Investing in technology to streamline ordering and delivery

🔟 10. MDS Nordion

Headquarters: Canada
Key Offering: Manufacturing and global distribution of radiopharmaceuticals, including Samarium‑153 EDTMP

MDS Nordion maintains a global presence with a strong focus on quality, regulatory compliance, and research support for radiopharmaceutical therapies.

Sustainability & Growth Initiatives:

• Ensuring high‑quality production through rigorous quality systems
• Expanding global distribution networks to reach underserved markets
• Investing in research collaborations to develop next‑generation formulations
• Maintaining compliance with international regulatory standards

Samarium‑153 EDTMP Bone Pain Palliation Radiopharmaceutical Market – View in Detailed Research Report

Samarium‑153 EDTMP Bone Pain Palliation Radiopharmaceutical Market – View in Detailed Research Report

🌍 Outlook: The Future of Samarium‑153 EDTMP Bone Pain Palliation Radiopharmaceutical Market

The Samarium‑153 EDTMP market is experiencing steady growth, driven by an aging global population, increasing prevalence of bone metastases, and expanding nuclear medicine infrastructure. As oncology centers adopt advanced radiopharmaceutical therapies, the demand for effective bone pain palliation solutions continues to rise. Emerging technologies in imaging and treatment planning are enhancing patient selection and therapeutic outcomes, further propelling market expansion.

📈 Key Trends Shaping the Market:

• Rising adoption of Samarium‑153 EDTMP in specialized oncology centers worldwide
• Advancements in diagnostic imaging (bone scans, PET/CT) enabling earlier and more accurate detection of bone metastases
• Integration of Samarium‑153 EDTMP with other pain‑management modalities such as opioids, bisphosphonates, and external beam radiation
• Development of next‑generation formulations to reduce myelosuppression and improve patient safety
• Expansion into emerging markets with growing cancer burdens and increasing nuclear medicine capabilities
• Digitalization of supply chains and improved cold‑chain logistics for short‑lived isotopes